Peptide research profile

ModGRF 1-29

Also known as CJC-1295 No DAC · Modified GRF(1-29)

A tetrasubstituted 29-residue GHRH analogue without the albumin-binding Drug Affinity Complex. It must not be conflated with long-acting CJC-1295 DAC.

  • Growth hormone signaling
Preclinical-heavy2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The 200 mcg nightly, five-days-on/two-days-off entry describes the calculator library—not a tested human no-DAC regimen. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset200 mcg / day
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNo no-DAC ceiling established
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Confirm the exact molecule before calculating: “CJC-1295” labels may refer to incompatible DAC and no-DAC forms.

Schedule literacy

Patterns described in source material

  • Nightly, 5 days on / 2 days off

    The cadence represented by the recorded calculator presets.

  • DAC-linked CJC-1295 uses much longer intervals

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context

The best-known human CJC-1295 trial used the long-acting DAC conjugate; it does not validate this preset.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    GHRH receptor signaling

    The modified 1-29 backbone is designed to retain pituitary GHRH activity.

  • 02

    Protease resistance

    Four substitutions aim to slow enzymatic degradation relative to native GRF(1-29).

  • 03

    Pulsatile GH research

    Short exposure is discussed in relation to endogenous GH pulses.

  • 04

    Formulation distinction

    DAC-linked and no-DAC products have fundamentally different pharmacokinetics.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Animal

    Modified backbone development

    Preclinical work characterized modified GRF analogues and the later albumin-bound DAC construct.

  • Human

    Human evidence is mainly DAC-linked

    The frequently cited 2006 trial tested long-acting CJC-1295 with DAC, not ModGRF 1-29 alone.

  • Review

    No-DAC clinical gap

    Direct controlled human pharmacokinetic and outcomes data for the no-DAC product are sparse.

Recorded protocol library

Amounts recorded for ModGRF 1-29

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Dose

    100 mcg

    Sign in for schedule, duration and source context.

  • 02

    Recorded reference

    200 mcg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Short-acting modified GHRH(1-29) analogue
Amino acids
29
Approx. MW
3367.9 Da
Origin / design
Protease-resistant GHRH backbone without the DAC linker

Important limitations

  • CJC-1295 DAC trial doses and half-life cannot be assigned to ModGRF 1-29.
  • Product naming is inconsistent and can conceal the presence or absence of the DAC linker.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. Human growth hormone-releasing factor 1-29 albumin bioconjugates activate the GRF receptorEndocrinology · 2005 · Animal
  2. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adultsJournal of Clinical Endocrinology & Metabolism · 2006 · Human

Related profiles